191 related articles for article (PubMed ID: 27091855)
1. Dramatic Survival Benefit with Nivolumab in Melanoma.
Cancer Discov; 2016 Jun; 6(6):OF7. PubMed ID: 27091855
[TBL] [Abstract][Full Text] [Related]
2. Nivolumab success in untreated metastatic melanoma.
Wilkinson E
Lancet Oncol; 2015 Jan; 16(1):e9. PubMed ID: 25638562
[No Abstract] [Full Text] [Related]
3. Nivolumab: A Review in Advanced Melanoma.
Scott LJ
Drugs; 2015 Aug; 75(12):1413-24. PubMed ID: 26220912
[TBL] [Abstract][Full Text] [Related]
4. [Not Available].
Mateus C; Libenciuc C; Robert C
Bull Cancer; 2016 Jun; 103(6 Suppl 1):S4-S11. PubMed ID: 27494973
[TBL] [Abstract][Full Text] [Related]
5. Immune Checkpoint Therapy in Melanoma.
Callahan MK
Cancer J; 2016; 22(2):73-80. PubMed ID: 27111901
[TBL] [Abstract][Full Text] [Related]
6. PD-1 Blockers.
Wolchok JD
Cell; 2015 Aug; 162(5):937. PubMed ID: 26317459
[TBL] [Abstract][Full Text] [Related]
7. Nivolumab in previously untreated melanoma without BRAF mutation.
Robert C; Long GV; Brady B; Dutriaux C; Maio M; Mortier L; Hassel JC; Rutkowski P; McNeil C; Kalinka-Warzocha E; Savage KJ; Hernberg MM; Lebbé C; Charles J; Mihalcioiu C; Chiarion-Sileni V; Mauch C; Cognetti F; Arance A; Schmidt H; Schadendorf D; Gogas H; Lundgren-Eriksson L; Horak C; Sharkey B; Waxman IM; Atkinson V; Ascierto PA
N Engl J Med; 2015 Jan; 372(4):320-30. PubMed ID: 25399552
[TBL] [Abstract][Full Text] [Related]
8. Nivolumab: targeting PD-1 to bolster antitumor immunity.
Brahmer JR; Hammers H; Lipson EJ
Future Oncol; 2015; 11(9):1307-26. PubMed ID: 25798726
[TBL] [Abstract][Full Text] [Related]
9. Nivolumab: Immunotherapy in Malignant Melanoma.
Bayless H; Schneider S
Clin J Oncol Nurs; 2015 Aug; 19(4):430-2. PubMed ID: 26207707
[TBL] [Abstract][Full Text] [Related]
10. The 'nivolution' in renal cell carcinoma: behind the scenes of clinical trials.
Buti S; Bersanelli M
Future Oncol; 2016 Sep; 12(18):2061-3. PubMed ID: 27168416
[No Abstract] [Full Text] [Related]
11. Immune checkpoint inhibitors and targeted therapies for metastatic melanoma: A network meta-analysis.
Pasquali S; Chiarion-Sileni V; Rossi CR; Mocellin S
Cancer Treat Rev; 2017 Mar; 54():34-42. PubMed ID: 28189914
[TBL] [Abstract][Full Text] [Related]
12. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients.
Ott PA; Hodi FS; Robert C
Clin Cancer Res; 2013 Oct; 19(19):5300-9. PubMed ID: 24089443
[TBL] [Abstract][Full Text] [Related]
13. Nivolumab and pembrolizumab as immune-modulating monoclonal antibodies targeting the PD-1 receptor to treat melanoma.
Faghfuri E; Faramarzi MA; Nikfar S; Abdollahi M
Expert Rev Anticancer Ther; 2015; 15(9):981-93. PubMed ID: 26313415
[TBL] [Abstract][Full Text] [Related]
14. Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab.
Weber J; Gibney G; Kudchadkar R; Yu B; Cheng P; Martinez AJ; Kroeger J; Richards A; McCormick L; Moberg V; Cronin H; Zhao X; Schell M; Chen YA
Cancer Immunol Res; 2016 Apr; 4(4):345-53. PubMed ID: 26873574
[TBL] [Abstract][Full Text] [Related]
15. Nivolumab provides favorable results in patients with advanced melanoma.
Dangi-Garimella S
Am J Manag Care; 2014 Mar; 20(5 Spec No.):E11. PubMed ID: 25618626
[No Abstract] [Full Text] [Related]
16. Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials.
Larkin J; Lao CD; Urba WJ; McDermott DF; Horak C; Jiang J; Wolchok JD
JAMA Oncol; 2015 Jul; 1(4):433-40. PubMed ID: 26181250
[TBL] [Abstract][Full Text] [Related]
17. Correlation between vitiligo occurrence and clinical benefit in advanced melanoma patients treated with nivolumab: A multi-institutional retrospective study.
Nakamura Y; Tanaka R; Asami Y; Teramoto Y; Imamura T; Sato S; Maruyama H; Fujisawa Y; Matsuya T; Fujimoto M; Yamamoto A
J Dermatol; 2017 Feb; 44(2):117-122. PubMed ID: 27510892
[TBL] [Abstract][Full Text] [Related]
18. Anti-PD-1 therapy in melanoma.
Homet Moreno B; Parisi G; Robert L; Ribas A
Semin Oncol; 2015 Jun; 42(3):466-73. PubMed ID: 25965365
[TBL] [Abstract][Full Text] [Related]
19. [Nivolumab for metastatic melanoma-basic knowledge and clinical data].
Yamazaki N; Maeda Y
Gan To Kagaku Ryoho; 2015 Apr; 42(4):434-8. PubMed ID: 26020984
[No Abstract] [Full Text] [Related]
20. [PD-1 Antibodies. A new therapeutic option for metastatic malignant melanoma].
Hafner C
Hautarzt; 2012 Sep; 63(9):724-5. PubMed ID: 22956035
[No Abstract] [Full Text] [Related]
[Next] [New Search]